Bright Minds Biosciences Inc. (DRUG) — Bright Minds Biosciences said management would present at investor and scientific conferences, highlighting its selective 5-HT2 agonist portfolio led by BMB-101 for drug-resistant epilepsy and other CNS disorders.
The update accompanied the company's broader plans to advance BMB-101 following positive Phase 2 data. It kept the epilepsy-focused developer in front of investors during a busy financing stretch for the sector.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.